The ratings of 5 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Jazz Pharmaceuticals Plc (JAZZ) declines this week from a C to a D. Jazz Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing and commercializing products to meet medical needs in neurology and psychiatry. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of JAZZ stock.

This week, Novartis AG Sponsored ADR (NVS) drops from a C to a D rating. Novartis AG Sponsored ADR manufactures pharmaceutical and consumer healthcare products. For more information, get Portfolio Grader’s complete analysis of NVS stock.

Valeant Pharmaceuticals International, Inc. (VRX) slips from a C to a D this week. Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VRX stock.

Slipping from a C to a D rating, Aratana Therapeutics, Inc. (PETX) takes a hit this week. The company also gets F’s in sales growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PETX stock.

CymaBay Therapeutics, Inc. (CBAY) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBAY stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.